Welcome to HandyLab, Inc.

Press Releases

FOR IMMEDIATE RELEASE
July, 2008
HandyLab, Inc. Announces the Release of Jaguar Automated PCR System
ANN ARBOR, MI - HandyLab, Inc., a developer of novel molecular diagnostic testing products, announces the release of the Jaguar Automated PCR System. This real time PCR System integrates sample preparation, nucleic acid extraction, and microfluidic amplification and detection into a single instrument. Two to twently-four tests can be run in 45 to 90 minutes from a raw patient sample.

The Jaguar Automated PCR System provides a solution for today's laboratory challenges: labor, training, 24/7 results and more. HandyLab's Jaguar System delivers a simplified molecular testing process by automatically performing all real time PCR processes,
while the unique microfluidic technology essentially eliminates the risk of amplified PCR contamination. According to Mark Powelson, Vice President, Sales and Marketing,
"Jaguar will provide 'TRUE AUTOMATION' for laboratories wanting to streamline their Laboratory Developed Tests and it is anticipated the reduction in time-to-result that
Jaguar provides will improve the clinical decision making process."

About HandyLab
HandyLab is dedicated to the development, manufacture and sale of novel molecular diagnostic products based on patented and proprietary microfluidic, miniaturized real-time PCR and nucleic acid extraction technologies.

June, 2008
HandyLab, Inc. to Partner with Nanogen, Inc.
SAN DIEGO - Nanogen, Inc. (Nasdaq: NGEN), developer of in vitro diagnostic products, announced that it has been awarded a new $10.4 million, two-year contract from the U.S. Centers for Disease Control and Prevention (CDC) to develop a multi-analyte molecular diagnostic assay for Influenza. The molecular diagnostic test will be developed in partnership with the Medical College of Wisconsin (MCW) and HandyLab, Inc. of Ann Arbor, MI. The test will be significantly more sensitive than current rapid flu tests and is expected to be conducted in less than half the time it takes to run current molecular tests. These tests are intended as a key component of the CDC's two-pronged approach to quickly identify and respond to a potential flu pandemic.

The Nanogen proposal to the CDC included the use of Nanogen's proprietary MGB probe technology for real time PCR and anticipates the use of off-the-shelf instrumentation for sample handling and detection, including the HandyLab Raider system, a microfluidic
real time PCR technology, which will significantly shorten time to result.

“Our collaboration with Nanogen on this project validates Raider's performance for microfluidic real-time PCR technology” said Mark Powelson, HandyLab's Vice President of Sales and Marketing, “Our technology contribution to this project is anticipated to redefine the way respiratory testing is done.”

About HandyLab
HandyLab is dedicated to the development, manufacture and sale of novel molecular diagnostic products based on patented and proprietary microfluidic, miniaturized real -time PCR and nucleic acid extraction technologies.

About Nanogen
About Nanogen, Inc.: Nanogen, Inc. develops diagnostic products that enable physicians to deliver improved patient care. Its products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and a range of infectious diseases. The company's products include molecular diagnostic kits and reagents, and kits for rapid point-of-care testing. Nanogen has pioneered the development of biomarkers, molecular biology technologies and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen's website at www.nanogen.com.
------------------------------------------------------------------------------------
June, 2008
HandyLab Announces Supply Agreement with Fisher HealthCare
Ann Arbor, MI – HandyLab, Inc., a developer of novel clinical diagnostic testing products,
announced a national supply agreement with Fisher HealthCare, part of Thermo Fisher Scientific Inc. Fisher HealthCare, under their brand Prima™, will distribute HandyLab's real-time PCR instrument known as “Raider.” Raider uses HandyLab's patented technology to perform automated, microfluidic nucleic acid amplification and detection. HandyLab's
unique microfluidic cartridge technology significantly minimizes the chance for amplified nucleic acid contamination. Results can be obtained from isolated nucleic acid in fifteen minutes. HandyLab's development of microfluidic nucleic acid analysis technology is being incorporated into novel instrumentation and reagents that can be used in both clinical diagnostic and industrial applications. Mark Powelson, HandyLab's Vice President of Sales and Marketing, commented, “We are excited about the opportunity to work with Fisher HealthCare. Their direct sales and comprehensive channel network will allow customers convenient access to our new product lines.”

About Thermo Fisher Scientifict
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com
-------------------------------------------------------------------------------------------------------------------------------

February, 2008
HandyLab Announces Raider Real Time PCR System
Ann Arbor, MI – HandyLab, Inc., a developer of novel molecular diagnostic testing products, announced the release of its Raider Real-Time PCR Instrument. Nucleic acid testing reagents for a variety of sample matrices and tests will be available soon after the release of the Raider Instrument. Raider provides automated, microfluidic nucleic acid amplification
and detection with results available from purified nucleic acid in less than fifteen minutes.

HandyLab's novel microfluidic instrumentation and nucleic acid reagents can be used in both clinical and industrial applications. According to Mark Powelson, VP of sales and marketing, “The release of the Raider System is the first step in achieving our vision of fast, easy to use nucleic acid testing systems for any size laboratory - thus, better serving diverse patient populations.”

About HandyLab
HandyLab is dedicated to the development, manufacture and sale of novel molecular diagnostic products based on patented and proprietary microfluidic, miniaturized real-time PCR and nucleic acid extraction technologies.
------------------------------------------------------------------------------------------------------------------------
Press Release Archives | 2005| 2006